Contracts › 75N91022F00002
75N91022F00002: Title: Bladder Cancer Chemoprevention Using the Androgen Receptor Inhibitor Apalutamide
Awarded to University of Oklahoma by National Institutes of Health (NIH).
$1.4Mobligated
$1.4Mpotential value
04 February 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N91022F00002 |
|---|---|
| Vehicle | 75N91019D00020 |
| Awardee | University of Oklahoma |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NIH NCI |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | OK |
| Offers received | 2 |
| Period of performance | 05 August 2022 to 04 February 2027 |
| Potential end | 04 February 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record